1-[6-methyl-4-(thiophen-2-ylmethylamino)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]indazole-4-carboxamide
C20H19N7OS — CID 122685300
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[6-methyl-4-(thiophen-2-ylmethylamino)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]indazole-4-carboxamide
1-[6-methyl-4-(thiophen-2-ylmethylamino)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]indazole-4-carboxamide (PubChem CID 122685300) has the molecular formula C20H19N7OS and a molecular weight of 405.49 g/mol. Its IUPAC name is 1-[6-methyl-4-(thiophen-2-ylmethylamino)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]indazole-4-carboxamide.
Molecular Properties
| Compound Name | 1-[6-methyl-4-(thiophen-2-ylmethylamino)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]indazole-4-carboxamide |
|---|---|
| PubChem CID | 122685300 |
| Molecular Formula | C20H19N7OS |
| Molecular Weight | 405.49 g/mol |
| Exact Mass | 405.14 |
| IUPAC Name | 1-[6-methyl-4-(thiophen-2-ylmethylamino)-5,7-dihydropyrrolo[3,4-d]pyrimidin-2-yl]indazole-4-carboxamide |
| SMILES | CN1Cc2nc(-n3ncc4c(C(N)=O)cccc43)nc(NCc3cccs3)c2C1 |
| InChI | InChI=1S/C20H19N7OS/c1-26-10-15-16(11-26)24-20(25-19(15)22-8-12-4-3-7-29-12)27-17-6-2-5-13(18(21)28)14(17)9-23-27/h2-7,9H,8,10-11H2,1H3,(H2,21,28)(H,22,24,25) |
| InChIKey | CFINHHDEBKZDFP-UHFFFAOYSA-N |
| XLogP | 2.53 |
| TPSA | 101.96 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 405.49 |
| LogP ≤ 5 | 2.53 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122685300 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.